Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030

Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030

  • June 2020 •
  • 100 pages •
  • Report ID: 5921865 •
  • Format: PDF
‘Treatment-resistant depression (TRD)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Treatment-resistant depression, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Treatment-resistant depression (TRD) Disease Understanding
Treatment-resistant depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options. MDD is a mood disorder that causes a persistent feeling of sadness and loss of interest, which can interfere with day-to-day life. Depression lasting at least 2 weeks along with meeting about five or more of the DSM-V criteria (of MDD) is considered as MDD.

Several definitions exist, but there is a lack of consensus on a universally accepted operational definition of TRD. However, each model is an inadequate response to at least two different classes of antidepressant pharmacotherapies, even with adequate adherence to the treatment at optimum dosage for sufficient duration.
Various demographic factors such as female gender, old age, lower education level and economic status, and presence of life stressors have been associated with poor treatment response. Along with this, comorbid medical conditions such as endocrinopathies, immune-mediated, neurologic, autoimmune, and psychiatric conditions increase the likelihood of poor response to treatment. The pathophysiology of TRD is poorly understood, but it is thought to be multifactorial.
Adults with TRD bear a heavy burden of disease. According to recent literature reviews, adults with TRD as compared with those with treatment-responsive depression tend to have longer episodes of depression, more previous psychiatric hospital admissions, higher symptom severity, and a greater risk of comorbid anxiety disorders. Various symptoms experienced by children include Guilt, feeling of emptiness, self-dislike, sense of failure, self-denigration, quality of mood, fears, and phobias, suicidal attempts, etc.
Several factors create obstacles to adequate treatment of depression in the elderly. Medical co-morbidity, being very common in the elderly, may mask the depressive illness or lead medical practitioners to conclude that the symptoms of lowered mood are a component of the physical disorder. Elderly depressed patients may present with somatic complaints, such as pain, anorexia, or constipation, and lead to unnecessary physical investigations while neglecting the psychological symptoms. Memory problems and concentration difficulties may be the presenting complaints, and these may result in a misdiagnosis of dementia; this has been referred to as pseudodementia.

<>Treatment-resistant depression (TRD) Epidemiology
The Treatment-resistant depression epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant depression epidemiology segmented as the Total diagnosed Prevalent of Treatment-resistant depression, Gender-specific cases, Age-specific cases. The report includes the Prevalent scenario of Treatment-resistant depression symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

<>Country Wise- Treatment-resistant depression (TRD) Epidemiology
The epidemiology segment also provides the Treatment-resistant depression (TRD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total diagnosed prevalent population of Treatment-resistant depression Associated in 7MM countries estimated to be 4,464,781 cases in 2017.
• As per the estimates, the United States has the highest Prevalent population of Treatment-resistant depression with 3,083,238 cases in 2017.
• Among the EU5 countries, the UK had the highest Prevalent population of Treatment-resistant depression. On the other hand, Italy had the lowest Prevalent population with 45,641 in 2017.

Scope of the Report
• Treatment-resistant depression (TRD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• Treatment-resistant depression (TRD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Treatment-resistant depression (TRD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Treatment-resistant depression (TRD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Treatment-resistant depression
• The report provides the segmentation of the Treatment-resistant depression (TRD) epidemiology by Prevalent Cases of Treatment-resistant depression (TRD) in 7MM
• The report provides the segmentation of the Treatment-resistant depression (TRD) epidemiology by Gender-specific Prevalent Cases of Treatment-resistant depression (TRD) in 7MM
• The report provides the segmentation of the Treatment-resistant depression (TRD) epidemiology by Age-specific Prevalent Cases of Treatment-resistant depression (TRD) in 7MM

Report Highlights

<>• 11-Year Forecast of Treatment-resistant depression (TRD) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Treatment-resistant depression (TRD)
• Prevalent Cases according to segmentation: Gender-specific Prevalence of Treatment-resistant depression (TRD)
• Prevalent Cases according to segmentation: Age-specific Prevalence of Treatment-resistant depression (TRD)

KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population about Treatment-resistant depression (TRD)?
• What are the key findings of the Treatment-resistant depression (TRD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Treatment-resistant depression (TRD) across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the Treatment-resistant depression?
• What are the currently available treatments of Treatment-resistant depression?

Reasons to buy
The Treatment-resistant depression (TRD) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Treatment-resistant depression (TRD) market
• Quantify patient populations in the global Treatment-resistant depression (TRD) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Treatment-resistant depression (TRD) therapeutics in each of the markets covered
• Understand the magnitude of Treatment-resistant depression (TRD) population by its Prevalence cases
• Understand the magnitude of Treatment-resistant depression (TRD) population by its Gender-specific cases
• Understand the magnitude of Treatment-resistant depression (TRD) population by its Age-specific cases
• The Treatment-resistant depression (TRD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Treatment-resistant depression (TRD) Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

<>• Patient Segmentation
• Disease Risk and Burden

<>• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
The estimated 12-month prevalence of DSM-IV MDE is lower in Italy and Germany with 3.0 ± 0.2%; followed by Spain as 4.0 ± 0.3%, and highest in France with 5.9 ± 0.6%. The average age of onset ascertained retrospectively was 25.7 in the high-income countries and women have a twofold increased risk of MDE compared with men. The patient pool was further analyzed with age categorization such as 18–34, 35–49, 50–64, and 65+. Among this age categorization, the occurrence of MDD has increased with increasing age, however, it has decreased in the older age group after 65 years. (Bromet E et al.)